We scan new podcasts and send you the top 5 insights daily.
Susanna Banerjee found that blood ctDNA tests frequently missed KRAS mutations within the RAMP-201 study cohort. She emphasizes that clinicians must obtain tissue biopsies rather than relying on circulating tumor DNA, as KRAS status directs treatment outcomes for up to 30% of patients.
While liquid biopsies are a valuable, less invasive tool, a negative result is inconclusive for ruling out actionable mutations in NSCLC. It may simply mean the tumor isn't shedding enough DNA. Therefore, a negative liquid biopsy should never be the final word; it must be followed by a tissue biopsy to ensure patients don't miss out on targeted therapies.
Dr. Wander favors liquid biopsies for tracking disease progression because they are safer and easier for patients. While acknowledging that tissue biopsies can sometimes detect mutations missed by liquid ones (10-30% discordance), he believes rapidly advancing technology will soon minimize these discrepancies, making them the standard for monitoring.
While ctDNA is a powerful tool, it is not interchangeable with tissue testing for PI3K pathway alterations. Analysis from Capitello-291 showed PTEN deletions were the most discordant, with 11% of pathway alterations found only in tissue. This highlights the need for a complementary strategy, using both methods to ensure all eligible patients are identified for targeted therapy.
While liquid biopsies (ctDNA) excel at detecting mutations, tissue biopsies are irreplaceable for assessing the fundamental biology of the most life-threatening metastatic sites. For instance, a direct liver biopsy is needed to confirm estrogen receptor expression, a critical factor that ctDNA cannot determine.
Clinicians must recognize that liquid and solid biopsies show significant discordance. ESR1 mutations are more frequently detected in liquid assays, while PIK3CA mutations are more often found in solid tissue. This variability by gene directly impacts the optimal testing strategy for patients.
Even with contemporaneously collected samples, biomarker concordance between solid tissue and liquid biopsies is not uniform. Data shows ESR1 mutations are consistently more likely to be discordant—often found only in liquid—than PIK3CA or AKT mutations, reinforcing the need for gene-specific testing strategies.
Despite the risk of missing mutations, oncologists predominantly use convenient, less-invasive liquid biopsies to test for biomarkers at disease progression. A more invasive tissue biopsy is generally reserved for situations where the cancer behaves unexpectedly, such as a sudden shift from bone-only to visceral disease, which might suggest a missed biological driver.
This cancer is a "low-shedding" tumor, making circulating tumor DNA (ctDNA) difficult to detect. A key study found only 32% of patients with measurable disease had detectable ctDNA, and the concordance for KRAS status with tumor sequencing was only 44%, mandating tissue-based testing.
In patients with liver metastases, a low tumor fraction can cause false-negative liquid biopsy (ctDNA) results. Clinicians recommend obtaining a tissue biopsy to confirm the absence of targetable mutations and ensure concordance, preventing misinformed treatment decisions based on potentially inaccurate ctDNA.
Performing dual analysis with both liquid and tissue biopsies at metastatic diagnosis establishes a comprehensive baseline. This strategy helps differentiate between clonal and later-acquired mutations, enabling more accurate interpretation of subsequent ctDNA monitoring for resistance.